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Abstract The aim of this study is to evaluate Breast
Imaging Reporting and Data Systems (BI-RADS) 4A/B
subcategory risk estimates for ductal carcinoma in situ
(DCIS) and invasive cancer (IC), determining whether
changing the proposed cutoffs to a higher biopsy threshold
could safely increase cancer-to-biopsy yields while mini-
mizing false-positive biopsies. A prospective clinical trial
was performed to evaluate BI-RADS 4 lesions from
women seen in clinic between January 2006 and March
2007. An experienced radiologist prospectively estimated a
percent risk-estimate for DCIS and IC. Truth was deter-
mined by histopathology or 4-year follow-up negative for
malignancy. Risk estimates were used to generate receiver-
operating characteristic (ROC) curves. Biopsy rates, can-
cer-to-biopsy yields, and type of malignancies missed were
then calculated across postulated risk thresholds. A total of
124 breast lesions were evaluated from 213 women. An
experienced radiologist gave highly accurate risk estimates
for IC, DCIS alone, or the combination with an area under
ROC curve of 0.91 (95 % CI 0.84–0.99) (p \ 0.001), 0.81
(95 % CI 0.69–0.93) (p = 0.011), and 0.89 (95 % CI
0.83–0.95) (p \ 0.001), respectively. The cancer-to-biopsy
yield was 30 %. Three hypothetical thresholds for inter-
vention were analyzed: (1) DCIS or IC C 10 %; (2)
DCIS C 50 % or IC C 10 %; and (3) IC C 10 %, which
translated to 22, 48, and 56 % of biopsies avoided; cancer-
to-biopsy yields of 36, 47, and 46 %; and associated
chance of missing an IC of 0, 1, and 2 %, respectively.
Expert radiologists estimate risk of IC and DCIS with a
high degree of accuracy. Increasing the cut off point for
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recommending biopsy, substituting with a short-term fol-
low-up protocol with biopsy if any change, may safely
reduce the number of false-positive biopsies.
Keywords False-positive biopsy  Mammography
screening  BI-RADS  Biopsy thresholds
Introduction
The diagnostic workup of a suspicious mammographic
finding includes taking biopsies to determine whether
abnormal findings represent malignancy, with the goal of
identifying invasive cancer (IC) at the earliest stage,
thereby reducing mortality. There is, however, a consid-
erable variation in the rate of biopsy across the United
States as well as internationally, with cancer-to-biopsy
yields relatively low, ranging from 22 to 33 % [1–4] and
over half a million breast biopsies performed annually [5].
In addition, negative surgical open biopsy rates have been
shown to be twice as high in the United States as they are
in the United Kingdom, despite similar cancer detection
rates [6]. Over a 10-year period, 61 % of women under-
going annual mammographic screening will be called back
for an abnormality, and 7–9 % will receive a false-positive
biopsy recommendation [7–9]. The negative consequences
of benign biopsies include fear, pain, anxiety, direct
financial expenses, indirect costs related to work missed,
and risk of complications [10–12].
A Breast Imaging Reporting and Data Systems (BI-
RADS) 4 assessment is given to lesions that carry a risk of
malignancy between 2 and 95 % and, in the United States,
most BI-RADS 4 lesions are biopsied (69–95 %) [13, 14].
The 4th Edition (2003) of the BI-RADS guidance chapter
provided more refined categories of risk within the BI-
RADS Category 4 creating three sub-categories (4A, 4B,
and 4C) [15], and the 5th Edition (2013) recommends risk
estimates for malignancy (Table 1) [16]. However, there is
no distinction between the risk of ductal carcinoma in situ
(DCIS) or IC, instead using an overall risk estimate for
malignancy. The opportunity of sub-classifying BI-RADS
4 is that low-risk 4A lesions may clinically be evaluated
separately and followed rather than immediately biopsied
as is done for most 4B and 4C lesions.
This pilot study evaluates the diagnostic accuracy of an
experienced radiologist in assigning separate risk estimates
for both DCIS and IC. We tested the impact of several
different thresholds for biopsy, using risk estimates, to
determine if more refined thresholds would safely reduce
false-positive biopsies, and whether there is a category of
risk for which immediate intervention could be safely
replaced with short-term follow-up similar to BI-RADS 3,
with little impact on delaying the diagnosis of conse-
quential invasive breast cancer.
Materials and methods
Patients
Data were prospectively collected from a cohort of 213
consecutive female patients that were referred for further
evaluation of a breast lesion to the Coordinated Diagnostic
Evaluation Program (CDEP) at the Breast Care Center at
the University of California, San Francisco, between Jan-
uary 1, 2006 and March 31, 2007. CDEP was initially
created as a multidisciplinary program for patients with
abnormal mammograms. This study was approved by IRB
and was HIPAA compliant. The cohort had a combined
224 lesions. The majority of women (161) were referred to
the clinic for a BI-RADS score of 0 or 4. Off the remaining
referred women, 7 had a BI-RADS 5 score, 30 had a BI-
RADS 1–3 score on a prior mammogram, and 15 were
referred for some other suspicious finding without a prior
mammogram or BI-RADS score. Women with BI-RADS
1–3 were referred to CDEP because of patient preference,
family history, or patient age. Patient demographics and
medical history were collected by questionnaire at each
examination. The patients had a multidisciplinary assess-
ment and followed standard care.
Radiological assessment
For this study, the 124 BI-RADS 4 or 5 lesions were
reviewed by a radiologist with 29 years of mammography
experience who was blinded to final outcomes and clinical
data. BI-RADS 4 lesions were subcategorized into A
through C lesions and prospectively assigned a percent
risk-estimate for DCIS and IC separately following
guidelines as described in BI-RADS 5th edition (Table 1)
[16]. The expert radiologist differentiated risk estimates for
lesions based on morphology such as classifying round,
coarse, vascular, or punctate microcalcifications as low-








Biopsy should be performed in the








Subcategories of BI-RADS 4 scoring with risk estimates for malig-
nancy included in American College of Radiology’s Breast Imaging-
Reporting and Data System, BI-RADS: Mammography [16]
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risk as opposed to pleomorphic or fine linear/branching
microcalcifications which were classified as higher risk.
Linear and segmental distributions were considered higher
risk than clustered or regional microcalcifications [3]. If an
asymmetric density or mass was associated with calcifi-
cations, then a risk of at least 50 % for IC was allocated
[19].
Final diagnosis
Pathological findings (core biopsy, fine-needle aspiration,
or surgical specimen) at the patient’s definitive intervention
served as the reference standard. For patients who declined
biopsy or surgical intervention, the reference standard was
a negative 4-year screening or diagnostic mammogram.
Statistical analysis
Stata and R software programs were used for statistical
analysis. Diagnostic accuracy was assessed using receiver-
operating characteristic (ROC) curves. ROC curves were
generated and area under the curve (AUC) calculated for
three groups of risk estimates: (1) risk estimate of IC versus
outcome of IC (n = 124); (2) risk estimate of DCIS in
cases with invasive risk estimates\2 % versus outcome of
DCIS (n = 52); and (3) highest risk estimate (DCIS or IC)
versus outcome of malignancy (n = 124). Lesions with
risk estimates for both DCIS and IC were categorized into
the IC risk estimate groups. We performed a logistic
regression of outcome (1 if patient had the outcome, 0 if
not) from the radiologist’s risk estimate for each of the
three outcomes: DCIS, IC, and any malignancy (either
DCIS or invasive or both).
Results
Study population
The cohort of 213 consecutive female patients, enrolled
from January 2006 to March 2007, had 224 total lesions
and most were seen at the CDEP clinic for the evaluation of
an abnormal mammogram with a BI-RADS score of 0, 4,
or 5. At the time of radiological assessment, priors were
reviewed in combination with additional imaging if
required. Four lesions did not have imaging for review and
88 lesions were determined to have BI-RADS scores 1, 2,
or 3 and were eliminated from this analysis. Of the
remaining BI-RADS 4 and 5 lesions, two were excluded
because the patient came to CDEP with a pathological
diagnosis, and six were excluded because appropriate fol-
low-up data were not available. Analysis was confined to
the remaining 116 BI-RADS 4 and 8 BI-RADS 5 lesions;
totaling 124 lesions from 108 patients. Figure 1 shows the
flow diagram of the lesions included in the study. For our
analysis, mean patient age at the CDEP appointment was
54.9 years ± 13.8 (SD). Additional patient characteristics
based on the 124 lesions are listed in Table 2.
Fig. 1 BI-RADS 4 and 5
lesions included in the final
analysis. In 213 consecutive
female patients, 224 lesions
were evaluated. Eighty-eight
lesions were excluded because
they were read as BI-RADS 1-3.
Two lesions had final
pathological diagnosis at
presentation and four lesions
had no imaging available. Off
BI-RADS 4 and 5 lesions, six
were excluded because they did
not have follow-up. The
remaining 124 lesions were
used for analysis
Breast Cancer Res Treat (2013) 139:769–777 771
123
Final diagnosis
Off the 124 lesions, definitive diagnosis was obtained via
biopsy or surgical excision for 115 lesions, yielding a biopsy
rate of 93 % for BI-RADS 4 and 5 lesions at the CDEP. For
7 % (n = 9) of the 124 lesions, benign outcome was con-
firmed by a negative mammogram at 4 years. Off these nine
lesions, two had been recommended for biopsy at CDEP, six
were downgraded to BI-RADS 3, and one with ‘tea-cup’
calcification had been recommended for routine screening.
Thirty-five of the 115 biopsied lesions were found to
have IC or DCIS, yielding an overall cancer-to-biopsy
yield at CDEP of 30 %. Pathological diagnosis was
determined by a core biopsy (n = 16), fine-needle aspira-
tion (n = 12), and excisional biopsy (n = 7). Twenty-three
of these lesions were IC, 12 of which also had accompa-
nying DCIS. Twelve lesions were diagnosed as DCIS
alone. Eighty-nine lesions (72 %) were found to be benign:
80 by biopsy and 9 by 4-year follow-up. A total of eight
benign lesions (6 %) were found to be high-risk lesions such
as atypical hyperplasia. Final pathological diagnoses of the
benign and malignant lesions are described in Table 3.
Discriminative ability of DCIS and IC risk estimation
by an experienced breast radiologist
Risk estimates for IC only, DCIS only, and both IC and
DCIS were above zero in 43 % (n = 54), 40 % (n = 53),
and 17 % (n = 17), respectively. The ROC curve assessing
the risk estimate for IC versus outcome of IC (n = 124)
had an AUC of 0.91 (95 % CI 0.84–0.99) (Fig. 2a). The
ROC curve assessing the risk estimate for DCIS alone was



















Presenting with symptoms (lump, pain, discharge)
Yes 38 31
No 86 69
Reason for referral to CDEPa
Abnormal screening mammogram 81 65
Abnormal diagnostic mammogram 98 79
Other abnormal index imaging 5 4
No abnormal index imaging 5 4
CDEP BI-RADS score
BI-RADS 4 116 94
BI-RADS 5 8 6
a Multiple selections are possible; percentages do not add to 100 %
b Lesions map to characteristics of 108 patients based on the fre-
quency of lesions




Invasive breast cancer 23 66
Metastatic breast cancer 1 3
IDC (5 Grade 1, 10 Grade 2, 2 Grade NOS) 17 49
ILC (2 Grade 2, 1 Grade NOS) 3 9
Malignant myoepithelioma 1 3
Unspecified IC 1 3




Acellular amorphous debris 1 1
Atypical ductal hyperplasiaa 3 4
Atypical Lobular Hyperplasiaa 2 3
Apocrine metaplasia 4 5
Benign 8 10
Benign microcalcifications 4 5
Cyst 5 6
Duct ectasia 2 3
Fibroadenoma 17 21
Fibroadipose tissue 1 1
Fibrocystic changes 15 19
Fibrosis 6 8
LCISa 3 4
Lobular hyperplasia 1 1
Proteinaceous debris and neutrophils 1 1
Sclerosing adenosis 3 4
Stromal hyperplasia 1 1
Usual ductal hyperplasia 3 4
No cancer at 2-year follow-upb Lesions
(N = 9)
NOS not otherwise specified
a High-risk lesions associated with an increased risk of breast cancer
b Nine lesions were followed without a biopsy and had no cancer at
2-year follow-up
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analyzed in those lesions with \2 % estimated risk of IC
(n = 52); the AUC was found to be 0.81 (95 % CI
0.69–0.93) (Fig. 2b). A third ROC curve (n = 124) was
generated to compare the expert reader’s highest risk
estimate (for DCIS or IC) with an outcome of malignancy
(DCIS or IC); the AUC was found to be 0.89 (95 % CI
0.83–0.95) (Fig. 2c).
Hypothetical biopsy thresholds: resultant biopsy rates,
cancer-to-biopsy yields
The radiologist’s risk estimates were stratified into BI-
RADS risk categories and the types of lesions that were
found for each category were identified and characterized
(Table 4). Several possible scenarios for new biopsy
thresholds are listed in Table 5 with defined categories for
biopsy. Lesions whose risk estimates fall between the
current thresholds (risk [2 % for either DCIS or IC) and
the new proposed biopsy thresholds would be recom-
mended for a 6-month follow-up and a subsequent biopsy
if a change is noted. Effects of raising the biopsy threshold
are shown in terms of malignant lesions missed and benign
biopsies avoided in Table 5 and Fig. 3. Under current
clinical guidelines for BI-RADS 4 and 5, all lesions in this
analysis would have been biopsied with a cancer-to-biopsy
yield of 28 %. The actual biopsies performed during CDEP
generated a cancer-to-biopsy yield of 30 %.
Figure 3 shows the fraction of biopsies and the conse-
quent cancer-to-biopsy yield for the three newly proposed
biopsy thresholds chosen from Table 5 and designated as
scenarios #1–3. The newly proposed biopsy thresholds are
described in the following three scenarios. Scenario (1) If
only lesions with risk estimates above 10 % for either
DCIS or IC were recommended for biopsy, the cancer-to-
biopsy yield would be 36 and 22 % of current biopsies
would be avoided. No malignancies would be missed. (2) If
only lesions with DCIS risk estimates above 50 % for
DCIS or above 10 % for IC were recommended for biopsy,
the cancer-to-biopsy yield would be 47 and 48 % of
biopsies would be avoided. The consequence was one stage
1A IC missed (IDC, grade 2, 3 mm) and four DCIS lesions
(including one grade 3 DCIS) missed. The IC would likely
be picked up at 6-month follow-up if change was observed.
(3) If the biopsy thresholds were increased such that lesions
were biopsied only if they received IC risk estimates
greater than or equal to 10 %, the cancer-to-biopsy yield
would be 46 %, and 56 % of biopsies would be avoided.
However, the diagnosis of two ICs (IDC, grade 2, 3 mm;
IDC, grade 1, 2.5 mm) and eight DCIS lesions (including
two grade 3 DCIS) would have been missed and postponed
by 6 months or more. Focusing only on diagnosing IC, the
percent of lesions where diagnosis would be postponed
would be 0 % (scenario #1), 1 % (scenario #2), and 2 %
(scenario #3). The total DCIS and IC lesions that would
have been recommended for a 6-month follow-up were 5 of
the 124 lesions (4 %) in scenario #2, and 10 lesions (8 %)
Fig. 2 ROC curve comparing the expert radiologist’s risk estimates
for a IC versus IC outcomes (n = 124) with an AUC of 0.91 (95 % CI
0.84–0.99), b DCIS versus DCIS outcome (n = 53) with an AUC of
0.81 (95 % CI 0.69–0.93), c DCIS or IC with outcome of malignancy
(DCIS or IC) (n = 124) with an AUC of 0.89 (95 % CI 0.83–0.95)
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Table 4 Malignancies identified within risk estimate categories
Corresponding BI-RADS category Risk estimate range (%) No. lesions Final diagnosis
DCIS IDC Inv Ca DCIS alone Benign
Gr. 1–2 Gr. 3
DCIS-4A 2–9 \2 8 0 0 8
0 0
DCIS-4B 10–49 \2 33 1a 4 28
3 1
DCIS-4C 50–94 \2 12 1b 4 7
3 1
Inv Ca-4A Any RE 2–9 18 0 0 18
0 0
Inv Ca-4B Any RE 10–49 25 1 3 21
2 1
Inv Ca-4C Any RE 50–94 23 15 1 7
1 0
Inv Ca-5 Any RE 95–100 5 5 0 0
0 0
Total 124 23 12 89
Data are number of lesions with risk estimates for DCIS or IC as percentages. Data to the right are number of lesions
Inv Ca invasive cancer, Gr grade
a IDC, grade 2, 3 mm (Stage 1A)
b IDC, grade 1, 2.5 mm (Stage 1A)
































IC or DCIS rec
6-month F/U N
(%)
All BI-RADS 4 & 5
cases (current
guidelines)
124 (100) 0 (0) 35 28 0 (0) 0 (0) 0 (0) 0 (0)
10 % B DCIS
or 2 % B IC RE
116 (94) 8 (6) 35 30 0 (0) 0 (0) 0 (0) 0 (0)
10 % B DCIS or
10 % B IC RE
(scenario #1)
97 (78) 27 (22) 35 36 0 (0) 0 (0) 0 (0) 0 (0)
50 % B DCIS
or 2 % B IC RE
83 (67) 41 (33) 30 36 4 (3) 1 (1) 1 (1) 5 (4)
50 % B DCIS
or 10 % B IC
RE (scenario #2)
64 (52) 60 (48) 30 47 4 (3) 1 (1) 1 (1) 5 (4)
2 % B IC RE 73 (59) 51 (41) 25 34 8 (6) 2 (2) 2 (2) 10 (8)
10 % B IC RE
(scenario #3)
54 (44) 70 (56) 25 46 8 (6) 2 (2) 2 (2) 10 (8)
Unless otherwise stated, data are the number of lesions with percentages in parentheses. The denominator is 124 lesions for all percentages
except for the positive predictive value of the cancer to biopsy yield
RE risk estimate, IC invasive cancer, Ca/Bx Yield cancer to biopsy yield, Rec recommend, Mo month
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in scenario #3. Table 5 shows greater detail of the IC and
DCIS cases that would have received a 6-month follow-up
option instead of biopsy.
Discussion
Current criticisms of mammography screening programs
include concern about overdiagnosis, the generation of
false positives, and associated biopsies [17, 18]. While
overdiagnosis is controversial for IC, there is a developing
disquiet about overtreatment of DCIS, especially low-to-
intermediate grade DCIS [19]. It is likely that majority of
these lesions would not progress to IC, and if they do
progress, the risk is 5–15 years from the original time of
detection. High-grade DCIS may be associated with a
higher risk of developing invasive breast cancer, and this
risk is usually within 5 years of diagnosis. However, most
DCIS is treated like invasive disease. Increasing awareness
of the potential for overtreatment is leading to a recon-
sideration of the approach to DCIS, especially for low-to-
intermediate grade DCIS, and a shift to explore chemo-
prevention as an alternative. Certainly, there is no urgency
to detect such lesions. This pilot study was designed to
determine whether it was possible to give a separate risk
estimate for DCIS and IC and to lay the groundwork for
predicting biologic type. Increasingly, we understand that
breast cancer is a heterogeneous collection of diseases,
where the tempo of disease ranges from indolent to
aggressive. The results of this study show that an experi-
enced radiologist can accurately provide risk estimates for
both DCIS and IC. Revising thresholds for biopsy dem-
onstrates that there is only a very low risk of delaying
diagnosis, and the lesions for which diagnosis is delayed
appear to be those with more indolent behavior. If these
risk estimates can be validated by a larger study, then they
could be used to place some calcifications in the BI-RADS
4A, 3, or even 2 categories and generate new biopsy
threshold recommendations.
Given the substantial number of biopsies performed for
benign lesions we sought to identify potential new
thresholds to refine biopsy recommendations and to opti-
mize management. Experienced mammographers are likely
to be highly accurate in their ability to assign more refined
risk estimates of both DCIS and IC, as set by BI-RADS
subcategories. These categories can be used to assign new
biopsy thresholds that may result in safely avoiding many
benign biopsies, which is bourn out by some units reporting
a high PPV for malignancy.
In this study of 124 lesions, 2 hypothetical thresholds for
biopsy, scenario #1 and #2, seem most promising. In this
pilot study, a biopsy threshold of C 10 % DCIS or C 10 %
IC risk (scenario #1) avoids 22 % of biopsies with a can-
cer-to-biopsy yield of 36 % without delaying diagnosis for
any malignant lesions. A biopsy threshold of C 50 % DCIS
or C 10 % IC risk (scenario #2) results in avoiding 48 %
of biopsies, a cancer-to-biopsy yield of 47 %, but post-
pones diagnosing one IC and four non-invasive (DCIS)
Fig. 3 Comparing biopsy
threshold scenarios. The
fraction of biopsies and the
consequent cancer-to-biopsy
yield of current guidelines,
biopsy 100 %; the CDEP
results; and three hypothetical
biopsy threshold scenarios. The
lesions recommending for
6-month follow-up in the
scenarios on the x-axis are one
IC (3 mm, ER?, low-grade
invasive ductal carcinoma
[IDC]) in scenario #2 and two
ICs in scenario #3. If we
consider high-grade DCIS,
scenario #2 recommended one
case and scenario #3
recommended two cases for
6-month follow-up
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lesions. However, the IC was only 3 mm and low grade,
and it is highly likely to have been identified 6 months
later, still as stage 1a or 1b, with little consequence.
The introduction of mammographic screening led to a
significant rise in detection of DCIS, which has become a
target for screening [20]. The question is whether only high-
grade DCIS should be a focus of early detection. DCIS now
accounts for 20–30 % of all ‘‘malignant’’ diagnoses of
breast cancer, almost entirely from screening. Yet after
removal of approximately 60,000 DCIS cases annually for
over 10 years, there has not been a concomitant drop in IC,
suggesting that many of these lesions would not necessarily
progress to IC if left undetected [17]. Although the natural
history of DCIS is unknown, autopsy data indicate the
existence of a reservoir of DCIS in the population that is
never diagnosed and never attains clinical relevance [21,
22]. The consequence of delayed diagnosis of DCIS is
likely to be negligible. In addition, there is a great value in
risk stratifying low and intermediate versus high-grade
DCIS. Low-grade DCIS lesions have an uncertain risk for
progression to IC, as our understanding of the natural his-
tory of these lesions is poor. After excision, the risk of an IC
developing ranges from 5 to 30 % over a period of 2–15
years after excision [23–25]. If a high-grade DCIS pro-
gresses, it will do so over a period of 2–5 years [26].
BI-RADS 4, with a wide range of risk of malignancy
from 2 to 95 %, does not differentiate between a low-grade
DCIS, which may never have clinical significance [27], and
a consequential IC [17]. BI-RADS 4 includes many
patients who do not have malignant or even high-risk
lesions. The results demonstrate that with new biopsy
thresholds, the United States can decrease biopsies per-
formed for benign lesions to approach the cancer-to-biopsy
yield rates of other countries such as Sweden (30–47 %)
[28] and the United Kingdom (50–64 %) [6, 29]. Focusing
on diagnosing IC or high-grade DCIS lesions may be one
way to arrive at a threshold that lowers false positives
while maintaining sensitivity for ICs.
BI-RADS 4 lesions that are ultimately benign are those
that are most frequently thought to have a risk of non-high-
grade DCIS. There is a fear of missing associated IC,
although that is usually only identified in conjunction with
the high-grade DCIS lesions that have fairly characteristic
appearances on mammogram and are usually assigned a
[50 % chance of being DCIS. The fact that DCIS is not an
emergency, and does not require urgent intervention, may
allow us to consider recommending a 6-month follow-up
instead of biopsy. This is unlikely to have an impact on
survival, even if the lesion ultimately is diagnosed as DCIS.
The fear of missing cancers is a potent driver of excess
biopsies. Although controversial, there is increasing support
for the view that some proportion of screen-detected cancers
are slow-growing low-risk tumors, with indolent behavior
[30–32]. A delay of 6 months in the detection of such lesions
is unlikely to cause harm. The challenge is to distinguish
benign and slow-growing lesions from those where there is
an urgent need for resolution, recommending a short-term
follow-up for the former and biopsy for the latter. For many
low-risk radiographic findings, evidence of growth over time
may help sort out which lesions require biopsy: IC lesions
will progress and change over 6 months of observation and
can be detected in a timely manner at an early stage.
The findings of this study demonstrate the potential
clinical utility of experienced radiologists, providing sep-
arate risk estimates for DCIS and IC. In this small study,
lesions that might have been missed and recommended for
a 6-month follow-up were likely to have little if any
immediate risk if diagnosis is delayed for 6 months. Biopsy
thresholds also give radiologists and clinicians the justifi-
cation and support for allowing disease dynamics to
determine what is consequential and worthy of bringing to
clinical attention [33].
This study has several weaknesses. First, as a pilot study,
we have a small number of cases, which may not be rep-
resentative. Also, intervention decisions may not be prop-
erly made at 6-month follow-up and diagnosis may be
delayed. Women may not fully understand risk and the
importance of follow-up. Lastly, only one experienced
radiologist generated the risk estimates for this study. Our
experienced radiologist’s predictive ability may not be
representative of other radiologists. We are in the process of
validating this hypothesis in a reader study of 750 BI-RADS
4 and 5 lesions across five University of California Medical
Centers as part of the Athena Breast Health Network. This
will test academic radiologists of varying experience. If
validated, we also plan to extend our study to community
radiologists to show that this can work outside of academia.
This study suggests that using a biopsy threshold of risk
estimates C50 % for DCIS and C10 % for IC may effec-
tively and potentially safely improve cancer-to-biopsy
yields. It was only intended as a pilot study to explore and
validate new thresholds for biopsy, and has subsequently
led to the above reader study. Management of lower risk
lesions with a 6-month observation may increase patient
anxiety and may only postpone biopsy, but may also enable
us to safely observe specific lesions and decrease the
biopsy rate. If validated, it will be necessary for clinicians
to educate their patients about the safety of observation and
communicate the plan for follow-up.
This pilot study found that following risk-based biopsy
thresholds for BI-RADS 4 lesions by recommending a
6-month follow-up for the lowest-risk lesions, reclassifying
to a BI-RADS 3 equivalent, may safely reduce biopsy rates
and increase cancer-to-biopsy yields. These thresholds are
not meant to be the definitive standards for biopsy but
rather a starting point to move forward to determine what
776 Breast Cancer Res Treat (2013) 139:769–777
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thresholds best improve cancer-to-biopsy yields while
avoiding a delay in diagnosis for consequential invasive
lesions.
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